Log in

NASDAQ:CFMS - ConforMIS Stock Price, Forecast & News

-0.07 (-4.29 %)
(As of 12/8/2019 04:26 AM ET)
Today's Range
Now: $1.56
50-Day Range
MA: $1.95
52-Week Range
Now: $1.56
Volume289,991 shs
Average Volume1.18 million shs
Market Capitalization$107.19 million
P/E RatioN/A
Dividend YieldN/A
Conformis, Inc, a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. Read More…

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Current SymbolNASDAQ:CFMS



Sales & Book Value

Annual Sales$89.79 million
Book Value$0.57 per share


Net Income$-43,370,000.00


Market Cap$107.19 million
Next Earnings Date2/5/2020 (Estimated)
OptionableNot Optionable

Receive CFMS News and Ratings via Email

Sign-up to receive the latest news and ratings for CFMS and its competitors with MarketBeat's FREE daily newsletter.

ConforMIS (NASDAQ:CFMS) Frequently Asked Questions

What is ConforMIS's stock symbol?

ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."

How were ConforMIS's earnings last quarter?

ConforMIS Inc (NASDAQ:CFMS) released its quarterly earnings data on Wednesday, October, 30th. The medical instruments supplier reported ($0.13) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.02. The medical instruments supplier had revenue of $17.30 million for the quarter, compared to the consensus estimate of $17.80 million. ConforMIS had a negative net margin of 41.36% and a negative return on equity of 115.71%. View ConforMIS's Earnings History.

When is ConforMIS's next earnings date?

ConforMIS is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for ConforMIS.

What price target have analysts set for CFMS?

2 Wall Street analysts have issued 12-month target prices for ConforMIS's shares. Their forecasts range from $3.00 to $4.00. On average, they anticipate ConforMIS's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 124.4% from the stock's current price. View Analyst Price Targets for ConforMIS.

What is the consensus analysts' recommendation for ConforMIS?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ConforMIS.

What are Wall Street analysts saying about ConforMIS stock?

Here are some recent quotes from research analysts about ConforMIS stock:
  • 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (11/4/2019)
  • 2. BTIG Research analysts commented, "$3 PT on Improving Trends We maintain our Buy rating and $3 PT following 1Q19 results which came in slightly ahead of expectations. Revenue of $20.6M compared favorably to BTIG/Street estimates of $20.0M/$20.1M. Noticeably CFMS saw encouraging uptake with both iTotal PS (+29% xFx) and iTotal Hip (still in the early stages of launch). GMs continued their upward trajectory, increasing 290 bps Y/Y to 47.6%. We believe CFMS’s worst days are behind it and the company is entering into a phase of improved and steady LSD growth driven by existing and recently launched products which give a growing distributor base a full recon line to sell. Recon surgery is clearly moving rapidly towards robotics but CFMS is going against the grain with an alternative option that may appeal to a group of surgeons who don’t want to be tied to a robotic system." (5/2/2019)

Has ConforMIS been receiving favorable news coverage?

News headlines about CFMS stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ConforMIS earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for ConforMIS.

Are investors shorting ConforMIS?

ConforMIS saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 4,570,000 shares, an increase of 23.2% from the October 31st total of 3,710,000 shares. Based on an average daily volume of 857,200 shares, the days-to-cover ratio is presently 5.3 days. Approximately 7.1% of the shares of the company are sold short. View ConforMIS's Current Options Chain.

Who are some of ConforMIS's key competitors?

What other stocks do shareholders of ConforMIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ConforMIS investors own include Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Alibaba Group (BABA), Intel (INTC), Starbucks (SBUX), AT&T (T) and Trevena (TRVN).

Who are ConforMIS's key executives?

ConforMIS's management team includes the folowing people:
  • Mr. Mark A. Augusti, CEO, Pres & Director (Age 53)
  • Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 55)
  • Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 53)
  • Mr. Ed Kilgallen, VP of Operations
  • Ms. Lisa M. Donnelly, Sr. VP of Global Marketing

When did ConforMIS IPO?

(CFMS) raised $135 million in an IPO on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Who are ConforMIS's major shareholders?

ConforMIS's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.87%), CAPROCK Group Inc. (0.29%), Gabelli Funds LLC (0.20%), Creative Planning (0.18%), Millennium Management LLC (0.12%) and Russell Investments Group Ltd. (0.05%). Company insiders that own ConforMIS stock include Archon Capital Management Llc, Bradley Langdale, Daniel Steines, David Cerveny, Mark A Augusti, Patricia A Davis, Paul S Weiner and Philipp Lang. View Institutional Ownership Trends for ConforMIS.

Which major investors are selling ConforMIS stock?

CFMS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC and Millennium Management LLC. Company insiders that have sold ConforMIS company stock in the last year include Archon Capital Management Llc, Bradley Langdale, Mark A Augusti, Patricia A Davis and Paul S Weiner. View Insider Buying and Selling for ConforMIS.

Which major investors are buying ConforMIS stock?

CFMS stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Creative Planning, CAPROCK Group Inc., Russell Investments Group Ltd., Gabelli Funds LLC and Teton Advisors Inc.. View Insider Buying and Selling for ConforMIS.

How do I buy shares of ConforMIS?

Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ConforMIS's stock price today?

One share of CFMS stock can currently be purchased for approximately $1.56.

How big of a company is ConforMIS?

ConforMIS has a market capitalization of $107.19 million and generates $89.79 million in revenue each year. The medical instruments supplier earns $-43,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. ConforMIS employs 262 workers across the globe.View Additional Information About ConforMIS.

What is ConforMIS's official website?

The official website for ConforMIS is http://www.conformis.com/.

How can I contact ConforMIS?

ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]

MarketBeat Community Rating for ConforMIS (NASDAQ CFMS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  263 (Vote Underperform)
Total Votes:  581
MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Preferred Stock

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel